ArticleTargeted oncology2024

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

Mara Persano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.